Results 191 to 200 of about 217,775 (266)

Old data, new tricks: Comprehensive computational analysis of 10 years of multi‐center EuroFlow acute myeloid leukemia diagnostic immunophenotypic data

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Acute myeloid leukemia (AML) is characterized by high genotypic and immunophenotypic heterogeneity. We collected an extensive dataset containing 5366 flow cytometry files from 885 AML patients, stained with the EuroFlow acute leukemia orientation tube (ALOT) and AML/MDS panel, acquired in a standardized way at eight centers over a period of 10 
Sarah Bonte, Rosan Olsman, Sofie Van Gassen, Sergio Matarraz, Neus Villamor, Stefan Nierkens, Paula Fernandez, Elaine Sobral da Costa, Carmen‐Mariana Aanei, Alberto Orfao, Jacques J. M. van Dongen, Yvan Saeys, Mattias Hofmans, Vincent H. J. van der Velden   +13 more
wiley   +1 more source

Successful allo-hematopoietic stem cell transplantation using washed hematopoietic stem cells in a pediatric patient complicated by acute myeloid leukemia and severe anaphylaxis to blood product. [PDF]

Pediatr Investig
Tian J, Zhu G, Qin M, Jia C, Ma S, Wang B, Luo Y.   +6 more
europepmc   +1 more source

Subset‐specific and tissue‐specific expression of NK‐cell markers and killer immunoglobulin‐like receptors: Implications for NK‐cell clonality assessment

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate immunophenotypic evaluation of natural killer (NK)‐cell neoplasms is challenging because NK‐cells lack somatically rearranged antigen receptors, are comprised of phenotypically distinct subsets, and exhibit tissue‐specific subset distribution. We developed a flow cytometry (FC) panel for NK‐cell immunophenotypic analysis and clonality
Valerie Woodings, Orrin Koepke, Jason E. Love, Alireza Torabi, Lianqun Qiu, Jonathan R. Fromm, Sindhu Cherian, Afshin Shameli   +7 more
wiley   +1 more source

In vivo modeling of stress erythropoiesis through targeted gene editing of rat hematopoietic stem cells. [PDF]

Blood Adv
van der Meulen SA, Roemhild K, Driessen M, van den Akker E, Nethe M.   +4 more
europepmc   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Engraftment of gene-edited hematopoietic stem cells after antibody-drug conjugate conditioning in nonhuman primates. [PDF]

Blood Adv
Murray J, Einhaus T, Radtke S, Bar KJ, Peterson CW, Kiem HP.   +5 more
europepmc   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Mesenchymal stromal cells modulate survival and regeneration of human hematopoietic stem cells via PGE2/cAMP signaling. [PDF]

Cell Death Dis
Muddineni SSNA, Katz-Even C, Zipin-Roitman A, Rasoulouniriana D, Singha Roy D, Aborgies R, Beider K, Raz Y, Solomon N, Hershkovitz G, Shulman Y, Chen R, Weizman E, Waskow C, Nagler A, Milyavsky M.   +15 more
europepmc   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Engineered hematopoietic stem cells give rise to therapeutic antibody secreting B cells

Porteus M, Luna S, Feist W, Utz A, Afaghani J, Miyauchi M, Ghanim H, Ekman F, Amaya A, Selvaraj S, Russkamp N, Schmiderer L.   +11 more
europepmc   +1 more source